Literature DB >> 19644577

Molecular biology of doxorubicin-induced cardiomyopathy.

J Umlauf1, M Horký.   

Abstract

The anthracycline doxorubicin is an antineoplastic agent, eliciting chronic cardiac toxicity. It occurs in patients after prolonged administration of doxorubicin, leading to congestive heart failure. The pathogenesis of the doxorubicin-induced car-diomyopathy is not well understood. The present article summarizes the unique effect of doxorubicin on cardiac-specific gene expression. In addition to binding to DNA, doxorubicin directly affects the function of a variety of proteins. Free radical generation, damage to mitochondria and active cell death are also critical in the development of doxorubicin-induced cardiac toxicity. Agents providing effective cardioprotection are also reviewed.

Entities:  

Keywords:  Cardiomyopathy; Cardioprotection; DNA damage; Doxorubicin; Mitochondrial dysfunction

Year:  2002        PMID: 19644577      PMCID: PMC2716188     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  24 in total

1.  A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes.

Authors:  R Jeyaseelan; C Poizat; R K Baker; S Abdishoo; L B Isterabadi; G E Lyons; L Kedes
Journal:  J Biol Chem       Date:  1997-09-05       Impact factor: 5.157

2.  Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes.

Authors:  R Jeyaseelan; C Poizat; H Y Wu; L Kedes
Journal:  J Biol Chem       Date:  1997-02-28       Impact factor: 5.157

3.  Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity.

Authors:  L Gille; H Nohl
Journal:  Free Radic Biol Med       Date:  1997       Impact factor: 7.376

4.  A calcium antagonist protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes.

Authors:  A Maeda; M Honda; T Kuramochi; T Takabatake
Journal:  Jpn Circ J       Date:  1999-02

5.  Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat.

Authors:  X Luo; Y Evrovsky; D Cole; J Trines; L N Benson; D C Lehotay
Journal:  Biochim Biophys Acta       Date:  1997-02-27

6.  TAFII250, Egr-1, and D-type cyclin expression in mice and neonatal rat cardiomyocytes treated with doxorubicin.

Authors:  N Saadane; L Alpert; L E Chalifour
Journal:  Am J Physiol       Date:  1999-03

7.  Doxorubicin cardiotoxicity: diastolic cardiac myocyte dysfunction as a result of impaired calcium handling in isolated cardiac myocytes.

Authors:  A Maeda; M Honda; T Kuramochi; T Takabatake
Journal:  Jpn Circ J       Date:  1998-07

8.  Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cells.

Authors:  N S Paranka; R T Dorr
Journal:  Anticancer Res       Date:  1994 Sep-Oct       Impact factor: 2.480

9.  In vivo prevention of adriamycin cardiotoxicity by cyclosporin A or FK506.

Authors:  I A Al-Nasser
Journal:  Toxicology       Date:  1998-11-16       Impact factor: 4.221

10.  A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity.

Authors:  K Adachi; Y Fujiura; F Mayumi; A Nozuhara; Y Sugiu; T Sakanashi; T Hidaka; H Toshima
Journal:  Biochem Biophys Res Commun       Date:  1993-09-15       Impact factor: 3.575

View more
  9 in total

1.  Effects of cardiac-restricted overexpression of the A(2A) adenosine receptor on adriamycin-induced cardiotoxicity.

Authors:  Eman A Hamad; Xue Li; Jianliang Song; Xue-Qian Zhang; Valerie Myers; Hajime Funakoshi; Jin Zhang; Jufang Wang; Jifen Li; David Swope; Ashley Madonick; John Farber; Glenn L Radice; Joseph Y Cheung; Tung O Chan; Arthur M Feldman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-02       Impact factor: 4.733

2.  Mechanisms and management of doxorubicin cardiotoxicity.

Authors:  Y Shi; M Moon; S Dawood; B McManus; P P Liu
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

3.  Catechin protects against oxidative stress and inflammatory-mediated cardiotoxicity in adriamycin-treated rats.

Authors:  Tarek A Abd El-Aziz; Randa H Mohamed; Heba F Pasha; Hisham R Abdel-Aziz
Journal:  Clin Exp Med       Date:  2011-11-12       Impact factor: 3.984

4.  Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis.

Authors:  R Jung; M W Wendeler; M Danevad; H Himmelbauer; R Gessner
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

5.  Nanoalginates via Inverse-Micelle Synthesis: Doxorubicin-Encapsulation and Breast Cancer Cytotoxicity.

Authors:  Justin G Rosch; Anna L Brown; Allison N DuRoss; Erin L DuRoss; Gaurav Sahay; Conroy Sun
Journal:  Nanoscale Res Lett       Date:  2018-11-03       Impact factor: 4.703

6.  The Effects of Neuropeptide Y Overexpression on the Mouse Model of Doxorubicin-Induced Cardiotoxicity.

Authors:  Minttu Mattila; Mirva Söderström; Liisa Ailanen; Eriika Savontaus; Mikko Savontaus
Journal:  Cardiovasc Toxicol       Date:  2020-06       Impact factor: 3.231

7.  Congo Red as a Supramolecular Carrier System for Doxorubicin: An Approach to Understanding the Mechanism of Action.

Authors:  Klaudia Kwiecińska; Anna Stachowicz-Kuśnierz; Beata Korchowiec; Maciej Roman; Wojciech M Kwiatek; Anna Jagusiak; Irena Roterman; Jacek Korchowiec
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

8.  Nuclear interaction between ADR-induced p65 and p53 mediates cardiac injury in iNOS (-/-) mice.

Authors:  Marsha P Cole; Jitbanjong Tangpong; Terry D Oberley; Luksana Chaiswing; Kinsley K Kiningham; Daret K St Clair
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

9.  Cardioprotective effect of vanillic acid against doxorubicin-induced cardiotoxicity in rat.

Authors:  Bahar Baniahmad; Leila Safaeian; Golnaz Vaseghi; Mohammad Rabbani; Behnoosh Mohammadi
Journal:  Res Pharm Sci       Date:  2020-02-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.